Esperion Therapeutics Inc. (NASDAQ:ESPR) rose 2.6% during mid-day trading on Wednesday . The company traded as high as $11.34 and last traded at $11.18, with a volume of 185,758 shares. The stock had previously closed at $10.90.

ESPR has been the topic of a number of research reports. Lake Street Capital reduced their target price on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, June 29th. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. WallachBeth Capital lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 target price on the stock. in a report on Tuesday, July 5th. JMP Securities reiterated a “buy” rating and set a $67.00 target price on shares of Esperion Therapeutics in a report on Thursday, June 16th. Finally, Vetr raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 price objective on the stock in a research report on Monday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Esperion Therapeutics currently has an average rating of “Hold” and a consensus target price of $25.47.

The firm’s market cap is $255.96 million. The stock has a 50-day moving average of $13.47 and a 200 day moving average of $15.52.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.09. On average, analysts anticipate that Esperion Therapeutics Inc. will post ($3.57) earnings per share for the current fiscal year.

In other Esperion Therapeutics news, Director Mark E. Mcgovern acquired 5,000 shares of Esperion Therapeutics stock in a transaction dated Wednesday, July 6th. The stock was bought at an average cost of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at $6,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Timothy M. Mayleben acquired 7,000 shares of Esperion Therapeutics stock in a transaction dated Wednesday, May 4th. The stock was acquired at an average cost of $14.85 per share, with a total value of $103,950.00. Following the completion of the transaction, the chief executive officer now directly owns 41,614 shares of the company’s stock, valued at approximately $617,967.90. The disclosure for this purchase can be found here.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.